Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma - Expert Perspectives on AQUILA Phase 3 Trial and FDA Approval

Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Explore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.

Early intervention in myeloma treatment addresses critical patient needs, highlighting new trial data and the importance of tailored therapies for better outcomes.

The AQUILA trial explores a fixed-duration therapy for myeloma, aiming to balance effective treatment with reduced long-term toxicity for patients.

Explore the AKELA trial's findings on patient characteristics and the impact of daratumumab on progression-free survival in myeloma treatment.

Experts discuss the impact of daratumumab on smoldering myeloma, exploring survival rates, treatment options, and the importance of clinical trials.